

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jul 2026

### Evaluation of prevalence of Augmented renal clearance (ARC) and serum concentration of Meropenem with two different dosing regimens in critically ill patients

#### Protocol summary

##### Study aim

Evaluation of prevalence of Augmented renal clearance (ARC) and serum concentration of Meropenem with two different dosing regimens in patients with ARC

##### Design

Pre-post intervention, randomized, open label clinical trial

##### Settings and conduct

On the first day of the study, patients will be evaluated according to Augmented renal clearance (ARC) and Augmented renal clearance in trauma intensive Care (ARCTIC) scoring systems and for patients who categorized as high-risk based on these systems, 12-hour creatinine clearance will be measured on days 0, 3, 7, 10 and 14. Subjects with creatinine clearance 130 ml/min and above will be recruited. For patients who will be treated with meropenem 3g daily (1 gram three times a day), based on physician in charge decision, after 24 hours, blood samples will be drawn, one hour after end of the infusion (peak concentration) and half an hour before receiving the next dose (trough concentration), in order to measure the meropenem serum concentration. Then the dosage adjustment will be done and will increase to 6g daily (2 grams three times a day). Next set of same blood samples will be drawn 24 hours after dose change to measure new peak and trough meropenem serum concentrations.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: serum creatinin 0.7mg/dl and lower, Sequential Organ Failure Assessment (SOFA) score 4 and lower, Augmented renal clearance (ARC) scoring 7 and higher, Augmented renal clearance in trauma intensive Care (ARCTIC) scoring 7 and higher, 12 hour - Clearance creatinin 130 ml/min and higher Exclusion criteria: Age lower than 18, Pregnancy and Lactation

##### Intervention groups

First receive meropenem (Ronak daru) with a dose of 1 g

three times a day infusion over 4 hour, then dose up to to 2 g three times a day.

##### Main outcome variables

Serum concentration of meropenem

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20120703010178N19**

Registration date: **2020-02-07, 1398/11/18**

Registration timing: **registered\_while\_recruiting**

Last update: **2020-02-07, 1398/11/18**

Update count: **0**

##### Registration date

2020-02-07, 1398/11/18

##### Registrant information

##### Name

Mohammad Sistanizad

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8820 0087

##### Email address

sistanizadm@sbm.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-06-22, 1398/04/01

##### Expected recruitment end date

2020-03-19, 1398/12/29

##### Actual recruitment start date

empty  
**Actual recruitment end date**  
empty  
**Trial completion date**  
empty

**Scientific title**  
Evaluation of prevalence of Augmented renal clearance (ARC) and serum concentration of Meropenem with two different dosing regimens in critically ill patients

**Public title**  
Augmented renal clearance (ARC) and Meropenem concentration

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
serum creatinin 0.7mg/dl and lower Sequential Organ Failure Assessment (SOFA) score 4 and lower Augmented renal clearance (ARC ) scoring 7 and higher Augmented renal clearance in trauma intensive Care (ARCTIC) scoring 7 and higher 12 hour - Clearance creatinin 130 ml/min and higher

**Exclusion criteria:**  
Pregnancy and Lactation Age lower than 18 yr

**Age**  
From **18 years** old to **75 years** old

**Gender**  
Both

**Phase**  
2-3

**Groups that have been masked**  
*No information*

**Sample size**  
Target sample size: **20**

**Randomization (investigator's opinion)**  
N/A

**Randomization description**

**Blinding (investigator's opinion)**  
Not blinded

**Blinding description**

**Placebo**  
Not used

**Assignment**  
Single

**Other design features**

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

**Name of ethics committee**  
Ethics committee of Shahid Beheshti University of Medical Sciences, Faculties of Pharmacy and Nursin

**Street address**  
Faculty of pharmacy, Niayesh and Vali-e-Asr junction

**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1991953381

**Approval date**  
2018-05-28, 1397/03/07

**Ethics committee reference number**  
IR.SBMU.PHARMACY.REC.1398.164

## Health conditions studied

### 1

#### Description of health condition studied

Augmented renal clearance (ARC)

#### ICD-10 code

#### ICD-10 code description

## Primary outcomes

### 1

#### Description

Serum concentration of Meropenem

#### Timepoint

1 hour after end of infusion, 30 minute before next dose

#### Method of measurement

HPLC

### 2

#### Description

Serum creatinin

#### Timepoint

Daily from the beginning of the study to the 14th day of the study

#### Method of measurement

Laboratory apparatus, Calorimetric method

### 3

#### Description

Urine volume

#### Timepoint

0,3,7,10,14 day of enter to study

#### Method of measurement

Urine bag

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: Patients with creatinine clearance of more than or equal to 130 ml/min, based on 12-hr urine collection, who receive meropenem (Ronakpharm, Iran)

will be recruited in the study. Study subjects will receive meropenem, 1 g three times daily as 4-hr infusion. After 24 hours, at steady state, two blood samples, 1 hour after termination of infusion and 0.5 hour before next dose, will be gathered. Then the dose of meropenem will be increased to 2 g three times in day and again, after 24 hours, one hour after end of infusion and half an hour before receiving the next dose of meropenem the blood sample will be drawn. Meropenem concentration will be determined by HPLC method.

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Intensive Care Unit, Imam Hossein medical center

**Full name of responsible person**

Mohammad Sistanizad

**Street address**

Imam Hossein medical center, Shahid Madani Street,  
Nezam Abad Neighborhood

**City**

Tehran

**Province**

Tehran

**Postal code**

1617763141

**Phone**

+98 21 3437 9032

**Email**

info@ehmc.ir

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Afshin Zarghi

**Street address**

3rd Floor, School of Medicin. Next to Taleghani  
Hospital, Evin, Shahid Chamran High Way

**City**

Tehran

**Province**

Tehran

**Postal code**

1985717434

**Phone**

+98 21 2243 9951

**Email**

mpd@sbmu.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shahid Beheshti University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Mohammad Sistanizad

**Position**

Associated Professor/Clinical Pharmacy Specialist

**Latest degree**

Specialist

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Department of Clinical Pharmacy, Faculty of  
Pharmacy, Niayesh Highway

**City**

Tehran

**Province**

Tehran

**Postal code**

1991953381

**Phone**

+98 21 8820 0118

**Email**

sistanizadm@sbmu.ac.ir

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Mohammad Sistanizad

**Position**

Associated Professor, Clinical Pharmacy Specialist

**Latest degree**

Specialist

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

Department of Clinical Pharmacy, Faculty of  
Pharmacy, Niayesh Highway

**City**

Tehran

**Province**

Tehran  
**Postal code**  
1991953381  
**Phone**  
+98 21 8820 0118  
**Email**  
Sistanizadm@sbmu.ac.ir

1991953381  
**Phone**  
+98 21 8820 0118  
**Email**  
Hassanpour@sbmu.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Shahid Beheshti University of Medical Sciences  
**Full name of responsible person**  
Rezvan Hassanpour  
**Position**  
Resident  
**Latest degree**  
Medical doctor  
**Other areas of specialty/work**  
Medical Pharmacy  
**Street address**  
Department of Clinical Pharmacy, Faculty of  
Pharmacy, Niayesh Highway  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available